Neurogene Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-0.5%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$5.31next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
NGN-401 Embolden Registrational Trial Dosing Completion Quarterly2,500.0%Target: 25 participants dosed (exceeded initial target of 20)
Cash, Cash Equivalents and Short-Term Investments Quarterly243.2MTarget: Sufficient to fund operations through Q1 2028
NGN-401 Safety Profile (HLH Cases at 1E15 vg dose) Quarterly0.0Target: 0 cases of hemophagocytic lymphohistiocytosis (HLH)
Watch Items
- Updated Interim Phase 1/2 Safety and Efficacy DataTrigger: Presentation of 12+ months of follow-up data for all 10 participantsAction: Evaluate durability of multidomain functional gains and long-term safety profile to de-risk the upcoming registrational readout.
- Process Performance Qualification (PPQ) CampaignTrigger: Initiation of PPQ manufacturing campaignAction: Monitor CMC progress to ensure commercial-grade production readiness in support of a future BLA submission.
- Embolden Registrational Trial Topline DataTrigger: Topline results in H2 2027 (Primary endpoint: composite CGI-I score ≤ 3 and developmental milestone gain)Action: Verify if the trial achieves the pre-specified minimum response rate of 33% (8 of 24 ITT participants) to support BLA filing.
Research as of 20 Jun 2026